Q2 FY27 · NSE: SAKAR
Sakar Healthcare
Results filed 23 October 2026 · Market cap ₹2,102 crore · PE 49.1
- Revenue
- +51.9%
- on a year ago
- EBITDA
- +114.4%
- on a year ago
- Profit to shareholders
- +149.1%
- on a year ago
- EBITDA margin
- 27.8%
- −1.3 pts on last quarter
| Q2 FY27 | Q1 FY27 | vs previous quarter | Q2 FY26 | vs a year ago | |
|---|---|---|---|---|---|
| Revenue | 87.42 | 72.97 | +19.8% | 57.56 | +51.9% |
| Operating profit (EBIT) | 17.74 | 14.7 | +20.7% | 5.67 | +212.9% |
| Operating margin | 20.3% | 20.1% | +15 bps | 9.9% | +1044 bps |
| Other income | 0.28 | 1.54 | −81.8% | 1.21 | −76.9% |
| Exceptional items | 0 | 0 | – | 0 | – |
| Profit before exceptional items and tax | 16.02 | 14.58 | +9.9% | 5.36 | +198.9% |
| Profit to shareholders | 11.31 | 10.28 | +10.0% | 4.54 | +149.1% |
| Earnings per share (₹) | 5.08 | 4.62 | +10.0% | 2.03 | +150.2% |
Source: Sakar Healthcare Limited’s filing to NSE, 23 October 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.
Notes
No notes yet. They are written once the investor presentation or concall transcript is filed; transcripts usually come three to seven days after the call.
Sources
- Press release · filed 26-Oct-2026
- Investor presentation · filed 26-Oct-2026
- Figures: the company’s results filing with NSE, linked under the table.